NCT04584736View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL

Enrollment

283

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

July 16, 2020

Study Completion Date

October 12, 2020

Conditions

Primary Hypercholesterolemia

Interventions

DRUG

Livalo, Ezetrol

Pitavastatin+Ezetimibe Pitavastatin

Trial Locations (1)

134-701

Gangdong Sacred Heart Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY

NCT04584736 - To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia | Biotech Hunter | Biotech Hunter